thrombospondin-1 mimetic (ABT-510)

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

Angiogenesis inhibitor, VEGF inhibitor, Hepatocyte growth factor inhibitor, FGF inhibitor, IL-8 inhibitor

Related drugs:

‹

›

3ms

Visualization of nonsmall-cell lung cancer by near-infrared fluorescence imaging with tumor-targeting peptide ABT-510. (PubMed, Bioorg Chem)

High MPA-ABT-510 accumulation was evident in A549 intestinal metastases models, as evidenced by tumor-to-colorectal fluorescence ratios of 4.27 ± 0.11. MPA-ABT-510 exhibits superior imaging capabilities with minimal safety concerns, so it is a promising candidate for NSCLC surgical navigation.

3 months ago

Journal

CD36 (thrombospondin receptor)

thrombospondin-1 mimetic (ABT-510)

over1year

Preclinical Evaluation of CD36-Targeting Antiangiogenic Peptide ABT-510 for Near-Infrared Fluorescence Molecular Imaging of Colorectal Cancer. (PubMed, Anal Chem)

Furthermore, MPA-PEG-r-ABT-510 exhibited an antiangiogenic effect via tube information assay with human umbilical vein endothelial cells. Overall, MPA-PEG-r-ABT-510 presents rapid and precise tumor delineation characteristics, thereby making it a desirable tool for CRC imaging and surgical navigation.

over 1 year ago

Preclinical • Journal

CD36 (thrombospondin receptor)

thrombospondin-1 mimetic (ABT-510)